创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

柴志珍合方联合多参数生物反馈仪治疗慢性精神分裂症的疗效及机制研究

Efficacy and Mechanism of Chaizhizhen Composite Formula Combined with Multiparameter Biofeedback Instrument Therapy in the Treatment of Patients with Chronic Schizophrenia

  • 摘要: 目的 探讨柴志珍合方联合多参数生物反馈仪治疗慢性精神分裂症的临床疗效,并分析其对患者认知功能、炎症因子及神经递质/神经营养因子水平的影响。方法 选取河南省中医院精神心理科2020年5月至2023年6月收治的86例慢性精神分裂症患者,采用随机数字表法分为2组,每组43例。对照组单纯采用多参数生物反馈仪治疗,观察组采用柴志珍合方联合多参数生物反馈仪治疗。比较2组的治疗效果。结果 观察组临床总有效率为93.02%,显著高于对照组的79.07%(P<0.05)。治疗4周和随访4周时,观察组阳性与阴性症状量表评分显著低于同期对照组,中文版蒙特利尔认知评估量表评分显著高于同期对照组(均P<0.05);观察组血清白介素-8、白介素-2、肿瘤坏死因子-α水平显著低于同期对照组,去甲肾上腺素、5-羟色胺、脑源性神经营养因子及胶质细胞源性神经营养因子水平显著高于同期对照组(均P<0.05)。结论 柴志珍合方联合多参数生物反馈仪治疗慢性精神分裂症疗效确切,可有效改善患者精神症状与认知功能,其机制可能与调节炎症因子平衡、改善神经递质分泌及促进神经营养因子表达相关。

     

    Abstract: Objective To investigate the clinical efficacy of Chaizhizhen Composite Formula combined with multi-parameter biofeedback instrument therapy in the treatment of chronic schizophrenia, and to analyze its effects on patients’ cognitive function, inflammatory factors, and the level of neurotransmitter/neurotrophic factor. Methods A total of 86 patients with chronic schizophrenia admitted to the Department of Psychiatry and Psychology, Henan Provincial Hospital of Traditional Chinese Medicine from May 2020 to June 2023 were selected and divided into two groups, using a random number table method, with 43 cases in each. The control group was treated with a multi-parameter biofeedback instrument alone, while the observation group was treated with Chaizhizhen Composite Formula combined with multi-parameter biofeedback instrument therapy. The treatment outcomes were compared between the two groups. Results The total clinical effective rate of the observation group was 93.02%, which was significantly higher than 79.07% of the control group (P<0.05). At 4 weeks after treatment and 4 weeks of follow-up, the positive and negative syndrome scale scores of the observation group were significantly lower than those of the control group, while the Chinese version of Montreal cognitive assessment scores were significantly higher than those of the control group in the same period (all P<0.05). Furthermore, the observation group exhibited significantly lower serum levels of interleukin-8, interleukin-2, and tumor necrosis factor-α, and significantly higher levels of noradrenaline, 5-hydroxytryptamine, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor compared to the control group in the same period (all P<0.05). Conclusion Chaizhizhen Composite Formula combined with multi-parameter biofeedback instrument therapy demonstrates definite efficacy in patients with chronic schizophrenia, effectively improving their psychiatric symptoms and cognitive function. Its therapeutic mechanism may be associated with the regulation of inflammatory factors, enhancement of neurotransmitter secretion, and promotion of neurotrophic factor expression.

     

/

返回文章
返回